Form 4: Alnylam Pharmaceuticals Executive Sells Shares After Performance-Based Stock Unit Vesting

Alnylam Pharmaceuticals' CSO and EVP, Kevin Fitzgerald, sold a significant number of shares following the vesting of a performance-based stock unit.

Summary

• Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, sold a total of 3,000 shares of common stock on November 25, 2024, after a performance-based stock unit vested.
• The vesting was triggered by the company publicly reporting FDA acceptance of a new drug application for a therapeutic to treat ATTR amyloidosis with cardiomyopathy.
• Following the vesting, Fitzgerald sold 3,000 shares at $0.00, and then sold 2,490 shares between November 26 and November 27, 2024, at prices ranging from $247.77 to $254.48.
• These sales were partly to cover tax obligations related to the vesting of the stock units.
• Fitzgerald also holds 537 shares indirectly through a managed account.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction following a positive company milestone. While the stock sale might cause minor short-term fluctuations, the underlying reason for the vesting is positive. The sentiment is neutral to slightly positive.

Positives

• The vesting of the performance-based stock unit indicates the achievement of a significant milestone for Alnylam Pharmaceuticals, specifically the FDA acceptance of a new drug application.
• The positive clinical outcome from a Phase 3 study triggered the vesting of the stock units.

Negatives

• The sale of a significant number of shares by a top executive could be perceived negatively by some investors, although it is partly due to tax obligations.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term downward pressure on the stock price.
• The market may interpret the sales as a lack of confidence in the company's future prospects, although this is not necessarily the case.

Industry Context

This stock sale by an executive is a common occurrence after vesting events, particularly in the biotechnology sector where stock-based compensation is prevalent. The vesting event itself is tied to a significant regulatory milestone, which is positive for the company.

Comparison to Industry Standards

• Executive stock sales are a common practice across the pharmaceutical and biotech industries, especially after vesting periods.
• Companies like Regeneron, Vertex Pharmaceuticals, and Biogen also use stock-based compensation and their executives often sell shares after vesting.
• The size of the sale is not unusual for an executive at this level, and the fact that it is partially to cover tax obligations is also standard practice.
• The vesting of the stock units is tied to a specific performance milestone, which is a common practice in the industry to align executive compensation with company performance.

Stakeholder Impact

• Shareholders may experience minor short-term price fluctuations due to the stock sale.
• Employees may view the vesting as a positive sign of company progress.
• The positive clinical outcome and FDA acceptance of the new drug application are positive for all stakeholders.

Key Dates

Keywords

Alnylam Pharmaceuticals, stock sale, insider trading, performance-based stock unit, executive compensation, FDA approval, ATTR amyloidosis, clinical trial, Rule 10b5-1, vesting